You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NEW YORK (GenomeWeb News) – DiscoveRx today said that it has acquired BioSeek, maker of the BioMAP platform of cell-based disease models for drug screening. Financial terms of the deal were not disclosed.
NEW YORK (GenomeWeb News) – BioSeek today said that the US Environmental Protection Agency has extended the firm's contract to participate in the ToxCast screening program.
A research team led by scientists at proteomics firm Cellzome has developed a selective inhibitor to the PI3 kinase isoform PI3Kγ.
Cellzome will use the BioMap platform in its inflammatory disease drug discovery projects.
BioSeek will apply its BioMap predictive human disease models to screen Amylin's library.
The Japanese pharmaceutical developer has licensed the BioMap platform for drug toxicology research projects.
BioSeek will use its BioMap system to conduct screening for Ono Pharmaceuticals in its compound studies.
The acquisition will combine Asterand's tissue-based services for drug discovery with BioSeek's BioMap platform and human cell-based assays.
The firm will profile compounds for the second phase of the EPA initiative.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.